Amphion Innovations plc
Board Change
London and New York, 5 September 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses announces the appointment of Stephen Austin as an additional non-executive director effective immediately. Following a career as a corporate lawyer, qualified executive and corporate stockbroker, Stephen is now the Chief Investment Officer of Plumtree Capital Limited, an FCA authorised corporate finance firm.
Stephen will join the Compensation Committee (as chairman) and the Audit Committee.
Save as disclosed below, there are no further details required to be disclosed pursuant to schedule 2(g) of the AIM rules.
Stephen Michael Austin (age 51) is, or has been in the previous five years, a director or partner, of the following companies:
| Current Appointments | Past Appointments |
| EC Aquisitions plc | Wisdom Acquisitions plc |
| Plumtree Capital Limited | |
| Plumtree Opportunities Limited | |
| Plumtree Small Cap Credit LLP |
Stephen Austin currently owns 300,000 warrants in the Company. The warrants have an exercise price of 3.5 pence and expire 28 July 2019.
Richard Morgan, CEO, commented: “We have worked with Stephen for four years on a range of projects including the successful AIM IPOs of Motif Bio and Polarean Imaging and now welcome him to the Board”.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact
Amphion Innovations
Charlie Morgan
+1 212 210 6224
Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Emma Earl / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker)
David Hignell (Corporate Finance)
Vadim Alexandre (Corporate Broking)
+44 (0)20 3861 6600
Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
